Metabolon and Cleveland Clinic have entered into multi-year collaborative agreement to accelerate research, drug development and precision medicine.
Metabolon will leverage its proprietary platform to analyse a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic’s novel discoveries, improve speed of decision-making and accelerate clinical trials.
Metabolomics, the large-scale study of all small molecules in a biological system, provides a complete current-state functional readout of a biological system, helping researchers see beyond the genetic variation of individuals, by capturing the combined impact of genetic as well as external factors, such as the effect of drugs, diet, lifestyle and the microbiome on human health. Metabolomics can reveal important biomarkers that can enable understanding of a drug’s mechanism of action (MOA), pharmacodynamics, safety profile, and individual response to therapy.
“Metabolon is proud to contribute research to help accelerate important discoveries that could improve human health,” said Greg Michelotti, Scientific Director, Metabolon. “Metabolomics is an essential element of the multi-omics approach that is being employed by Cleveland Clinic to transform healthcare by understanding disease progression and therapeutic response more deeply.”
